CL2024002422A1 - Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos - Google Patents

Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos

Info

Publication number
CL2024002422A1
CL2024002422A1 CL2024002422A CL2024002422A CL2024002422A1 CL 2024002422 A1 CL2024002422 A1 CL 2024002422A1 CL 2024002422 A CL2024002422 A CL 2024002422A CL 2024002422 A CL2024002422 A CL 2024002422A CL 2024002422 A1 CL2024002422 A1 CL 2024002422A1
Authority
CL
Chile
Prior art keywords
targeting
compounds
radioligands
solvate
compositions
Prior art date
Application number
CL2024002422A
Other languages
English (en)
Spanish (es)
Inventor
Liu Fa
Original Assignee
Full Life Tech Hk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Full Life Tech Hk Limited filed Critical Full Life Tech Hk Limited
Publication of CL2024002422A1 publication Critical patent/CL2024002422A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002422A 2022-02-18 2024-08-13 Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos CL2024002422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263311621P 2022-02-18 2022-02-18

Publications (1)

Publication Number Publication Date
CL2024002422A1 true CL2024002422A1 (es) 2024-12-06

Family

ID=87579080

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002422A CL2024002422A1 (es) 2022-02-18 2024-08-13 Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos

Country Status (11)

Country Link
US (2) US12145926B2 (https=)
EP (1) EP4479040A1 (https=)
JP (1) JP2025506705A (https=)
KR (1) KR20240150464A (https=)
CN (1) CN119136796A (https=)
AU (1) AU2023221977A1 (https=)
CA (1) CA3243418A1 (https=)
CL (1) CL2024002422A1 (https=)
IL (1) IL314786A (https=)
MX (1) MX2024009858A (https=)
WO (1) WO2023158802A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
DE4307983A1 (de) 1993-03-13 1994-09-15 Beiersdorf Ag Wirkstoffe und kosmetische und dermatologische Zubereitungen
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof

Also Published As

Publication number Publication date
JP2025506705A (ja) 2025-03-13
EP4479040A1 (en) 2024-12-25
US12145926B2 (en) 2024-11-19
US20240287046A1 (en) 2024-08-29
WO2023158802A1 (en) 2023-08-24
CN119136796A (zh) 2024-12-13
US20250026739A1 (en) 2025-01-23
AU2023221977A1 (en) 2024-08-15
IL314786A (en) 2024-10-01
CA3243418A1 (en) 2023-08-24
KR20240150464A (ko) 2024-10-15
MX2024009858A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
CL2024002422A1 (es) Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
BR112023026747A2 (pt) Métodos e composições para direcionamento de pd-l1
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
CL2021002489A1 (es) Protacs que degradan el receptor de estrogeno.
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY36207A (es) Inhibidores de la syk
MY197419A (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
AR125209A1 (es) Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
MX2024010104A (es) Compuesto bicíclico condensado que contiene pirrolinona.
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
AR132362A1 (es) Conjugados que comprenden enlazadores escindibles
JOP20240269A1 (ar) حلقات كبيرة من إندازول و استخدامها
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
MX2022009753A (es) Composiciones y metodos para el tratamiento de la enfermedad de pompe.
CL2025001273A1 (es) Compuesto bicíclico fusionado
CO2024012868A2 (es) Derivado de imidazopiridazina, y método de preparación del mismo, composición farmacéutica del mismo y uso del mismo
CO2024016692A2 (es) Derivado de anillo de benceno sustituido con imidazopiridazina, método de preparación, composición farmacéutica y uso